NCT05510908 · ADVERSE EVENTS

Adverse events

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · Source last updated 2026-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: This study is observational study. Adverse events are not collected.
Other-event reporting threshold: 0%

This study is observational study. Adverse events are not collected.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
New, Primary or Recurrent Disease Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.	0 / 0	0 / 0	0 / 0
Metastic or Locally Advanced Cancer This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.	0 / 0	0 / 0	0 / 0
Prior Cancer Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: New, Primary or Recurrent Disease · EG001: Metastic or Locally Advanced Cancer · EG002: Prior Cancer

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

This study is observational study. Adverse events are not collected.

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
New, Primary or Recurrent Disease
deaths Num Affected
0
deaths Num At Risk
0
description
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
id
EG001
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Metastic or Locally Advanced Cancer
deaths Num Affected
0
deaths Num At Risk
0
description
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
id
EG002
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Prior Cancer

frequency Threshold

time Frame

This study is observational study. Adverse events are not collected.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice